Molecular diagnostic characteristics in Cervical cancer: ROS1/ALK mutation biomarker study (MARC study)
- Conditions
- Cervical cancer
- Registration Number
- JPRN-UMIN000053405
- Lead Sponsor
- Japanes Gynecology Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 250
Not provided
1. Patients with active concomitant malignancy* except breast cancer. *Includes synchronous multiple cancer and metachronous multiple cancer with less than 5 years of disease-free survival. However, excludes skin basal cell carcinoma, skin squamous cell carcinoma, and any other curable lesions with local therapy such as carcinoma in situ or intramucosal carcinoma. 2. Patients who are diagnosed with any other acute/chronic, physically/mentally severe diseases and judged by the primary physician as inappropriate to enroll in this study because of safety reasons or any influence on study outcomes. 3. Any other cases that are inappropriate to enroll in this study, judged by the study principal investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method